BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:Bolstering a Resurgence in Novel Approaches to Target Underlyi
 ng Pathology\, Address Disease Heterogeneity and Restore Hope in a More T
 ransformative Wave of ALS and FTD Therapies.\n\nUniting ALS Biotech\, Pha
 rma and Academia to Accelerate the Next Generation of ALS and FTD Therape
 utics.\n\nStrategic moves across the sector-from Eli Lilly's Alchemab-bac
 ked ALS expansion to BMS and insistro's genetically driven collaboration 
 and Clene Nanomedicine's regulatory-stage program-underscore the ALS comm
 unity’s continued commitment to advancing impactful therapies\, even in t
 he face of clinical setbacks.\n\nWith over 475 therapies in development\,
  and 157 active or enrolling trials\, and more than 350 companies activel
 y working in ALS\, and a global ALS market projected to grow from USD 667
 .3M in 2023 to USD 987.6M by 2030\, confidence is returning. Learnings\, 
 fuelled by stronger mechanistic hypotheses\, and more resilient translati
 onal strategies\, spanning TDP 43 loss and gain of function biology\, cry
 ptic exon regulation\, neuroinflammatory pathways\, and human relevant iP
 SC and 3D models\, the ALS community is leveraging these lessons to build
  smarter\, more predictive programs.\n\nUniting 100+ senior experts acros
 s discovery\, translational research\, clinical development\, regulatory 
 science\, investment\, and patient advocacy\, 30+ speakers from AbbVie\, 
 AskBio\, Biogen\, Eli Lilly\, Novartis\, QurAlis\, Prilenia Therapeutics\
 , Mitsubishi Tanabe Pharma\, uniQure\, ROME Therapeutics\, Everything ALS
 \, Sanofi\, and more\, this is the definitive forum restoring hope across
  the ALS and FTD community.\n\nURLs:Website: https://go.evvnt.com/3463680
 -0?pid=185Tickets: https://go.evvnt.com/3463680-2?pid=185Brochure: https:
 //go.evvnt.com/3463680-3?pid=185\n\nDate and Time: On Tue\, 02 Jun 2026 0
 8:00 - Thu\, 04 Jun 2026 17:00\n\nVenue Details: The Colonnade Hotel\, 12
 0 Huntington Avenue\, Boston\, Massachusetts\, 02116\, United States\n\nC
 ategory: Conferences | Science\, Health and Medicine | Pharmaceuticals\n\
 nPrices:Industry Pricing - Conference + Workshop Day: USD 3697.00\,Indust
 ry Pricing - Conference Only: USD 2699.00\,Service Provider Pricing - Con
 ference + Workshop Day: USD 4597.00\,Service Provider Pricing - Conferenc
 e Only: USD 3399.00\,Academic Pricing - Conference + Workshop Day: USD 29
 97.00\,Academic Pricing - Conference Only: USD 2299.00\n\nSpeakers: Arti 
 Patel\, Principal Scientist\, Neuroscience and Program Lead\, Novartis\, 
 Francisca Martinez-Raub\, Director\, Eli Lilly\, Joel Schwartz\, Director
 \, Scientific Digital Biomarkers Neuroscience\, Bristol Myers Squibb\, Jo
 yce Lo\, Associate Director\, Biogen\, Kelly Glajch\, Scientific Director
 \, Rare NeurologyNeuroscience Therapeutic Area Unit\, Takeda\, Ivan Nyark
 oDanquah\, Postdoctoral Fellow\, Sanofi\, Makoto Tamura\, Executive Direc
 tor of NeuroDiscovery Lab\, Tanabe Pharma America \, Murali Gopalakrishna
 n\, Global Head\, Neuroscience Search and Evaluation\, Corporate Strategy
  Officer\, AbbVie\, Yea Jin Kaeser-Woo\, Senior Director\, Eli Lilly\, Yu
 nfeng Huang\, Principal Scientist\, Biogen\, Christopher Shaw\, Chief Sci
 entific Officer and Clinical Advisor\, AviadoBio\, George Apostol\, Head 
 of Clinical Development\, UniQure\, Irina Antonijevic\, Chief Medical Off
 icer Trace\, Neuroscience\, Javier San Martin\, Chief Medical Officer\, L
 eonaBio\, Mansuo Lu Shannon\, Chief Scientific Officer\, Ask Bio\, Michae
 l Hayden\, Chief Executive Officer\, Prilenia\, Michael Thurn\, Chief Exe
 cutive Officer\, Neurizon\, Sandy Hinkley\, Vice President\, Head of Disc
 overy\, QurAlis\, Sarah Knutson\, Executive Director\, Early Discovery\, 
 ROME Therapeutics\, Christian Rubio\, Executive Director\, Everything ALS
 \, Eloise Jarvis\, Senior Researcher\, Beacon Research Operations\, Hanxi
 ong (Bear) Zhang\, Principal\, RA Capital Management\, Colin Hovingay\, V
 ice President of Rare and Orphan Diseases\, Critical Path Institute\, Joh
 n Replogle\, Director\, National Institutes of Health (NIH)\, Philip C. W
 ong\, Professor of Pathology\, John Hopkins Medicine\, Ruth Chia\, Staff 
 Scientist\, National Institutes of Health (NIH)\, Ignazio Di Giovanna\, V
 ice President\, Scientific Affairs\, Neurology Evestia\, Clinical \, Mass
 imiliano Bianchi\, Founder\, President and Chief Executive Officer\, Ulys
 ses Neuroscience\, Matthew Mandeville\, Senior Business Development Manag
 er\, BrainXell\n
DTEND:20260604T170000
DTSTAMP:20260501T045438Z
DTSTART:20260602T080000
LOCATION:The Colonnade Hotel\, 120\, Huntington Avenue\, Boston\, Massachu
 setts\, 02116\,
SEQUENCE:0
SUMMARY:Bolstering a Resurgence in Novel Approaches to Target Underlying P
 athology\, Address Disease Heterogeneity and Restore Hope in a More Trans
 formative...
UID:ac6e397a-cafb-4de7-b920-c6e49b181818
END:VEVENT
END:VCALENDAR